Abstract
Background: Breast cancer–related lymphedema (BCRL) is a sequela of cancer treatment that can impact quality of life. Interventions to address this impairment should be tailored for each lymphedema stage throughout the trajectory of care, from diagnosis of cancer throughout survivorship. Methods: Studies were included in this clinical practice guideline if the purpose was to investigate interventions intended to reduce lymphedema risk, interstitial fluid, or upper extremity volume in individuals during and after breast cancer treatment. This executive summary presents the recommendations on interventions developed from the evidence review, according to stage of BCRL to allow for clinical implementation based on patient presentation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
